GSK plc or Incyte Corporation: Who Manages SG&A Costs Better?

Managing SG&A Costs: A Tale of Two Companies

In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, GSK plc and Incyte Corporation have taken different paths in managing these costs. From 2014 to 2023, GSK's SG&A expenses have fluctuated, peaking in 2020 with a 39% increase from 2014, before dropping by 27% in 2022. In contrast, Incyte Corporation has seen a steady rise, with a remarkable 600% increase over the same period, reflecting its aggressive growth strategy. While GSK's expenses are significantly higher, Incyte's rapid increase suggests a focus on expansion and market penetration. This comparison highlights the strategic choices companies make in balancing cost management with growth ambitions. As the pharmaceutical landscape evolves, these strategies will play a pivotal role in shaping their future success.